KYBORA’s mission is to help life science companies achieve enduring success. Khai’s addition to our team allows us to provide additional value to our clients in China and Asia.
KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People’s Republic of China.
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA’s expertise in delivering global biopharma licensing deals and in the ophtalmology space
Princeton, NJ – October 12th, 2021 KYBORA is pleased to announce that Howard Lei (MBA, MS-IT, PMP) has joined its team as Senior Advisor, responsible for expanding KYBORA’s operations in China (Shanghai). Howard is an experienced pharmaceutical executive with over 20 years of consulting and industry experience in China and the US with companies such […]
KYBORA is pleased to announce that Dr. Leonid Parshenkov, MD has joined its team as Senior Advisor, responsible for expanding KYBORA’s operations in Russia, CIS/CEE, and Africa. Leonid is a seasoned pharma leader with broad international experience. He worked as the General Manager (GM) of Solvay and Abbott in Russia, then assumed the role of […]
Download full presentation here
Recently, KYBORA Managing Director Jean Chatellier had an opportunity to share insights with industry leader Sejelas’ Ask the Experts Interview Series about KYBORA, our clients, what led him to join the company, and what sets us apart. See the full article here: https://sejelas.com/jean-chatellier/
